Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zai Lab Limited - American Depositary Shares (NQ:ZLAB)

25.92 +1.25 (+5.07%)
Streaming Delayed Price Updated: 3:35 PM EDT, Sep 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zai Lab Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab (ZLAB) Q2 2026 Earnings Call Transcript ↗
Zoci advances toward global registrational trials as net product revenue rises 11%. 
Via The Motley Fool
Topics Earnings
News headline image
Zai Lab Q2 Earnings Call Highlights ↗
Zai Lab (NASDAQ:ZLAB) said its second-quarter net product revenue rose 11% sequentially to $105.8 million as the company continued to invest in a pipeline it expects to support a transition into a... 
Via MarketBeat
Topics Earnings
News headline image
Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab (ZLAB) Q1 2026 Earnings Transcript ↗
Zai Lab (ZLAB) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Zai Lab Announces Changes to Senior Leadership Team
From Zai Lab Limited
Via Business Wire
News headline image
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline ↗
Bright Minds Biosciences develops serotonin-based therapeutics for neurological and neuropsychiatric conditions in a pre-clinical model. 
Via The Motley Fool
Topics Intellectual Property Regulatory Compliance
News headline image
Why This Fund Added $12 Million to a Biotech Stock That's Now Down 58% in a Year ↗
ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model. 
Via The Motley Fool
Topics Economy Regulatory Compliance
News headline image
Zai Lab Receives U.S. FDA Fast Track Designation for Zocilurtatug Pelitecan (Zoci), a DLL3-Targeting ADC, for Treatment of Extrapulmonary Neuroendocrine Carcinomas (epNECs)
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Q1 Earnings Call Highlights ↗
Zai Lab (NASDAQ:ZLAB) reported a year-over-year decline in first-quarter 2026 product revenue as pressure on ZEJULA weighed on results, while management emphasized progress across its global oncology... 
Via MarketBeat
Topics Earnings
News headline image
Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Present New Data on Three Internally Developed Oncology Candidates at AACR 2026, Including Zocilurtatug Pelitecan, a DLL3-Targeting Antibody-Drug Conjugate (ADC)
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO™ (repotrectinib) for Patients with NTRK-Positive Solid Tumors
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis
From Zai Lab Limited
Via Business Wire
News headline image
Zai Lab Announces Updates to China’s National Reimbursement Drug List
From Zai Lab Limited
Via Business Wire
News headline image
Nuvation Bio (NUVB) Soars on IBTROZI's Blockbuster Launch and Stellar Q3 2025 Performance
Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025... 
Via MarketMinute
News headline image
Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates
From Zai Lab Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.